Volume 9, Issue 4 (10-2023)
Journal of Research in Applied and Basic Medical Sciences 2023, 9(4): 223-228 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rostamzadeh khameneh Z, Valizadeh N, Nemati M, Eishi A. Seroprevalence of cytomegalovirus infection in the patients with chronic lymphocytic leukemia. Journal of Research in Applied and Basic Medical Sciences 2023; 9 (4) :223-228
URL: http://ijrabms.umsu.ac.ir/article-1-223-en.html
URL: http://ijrabms.umsu.ac.ir/article-1-223-en.html
Associate Professor of Laboratory Sciences, Department of Laboratory Sciences, Solid Tumor Research Center, Cellular and Molecular Medicine Research Institute, Urmia University of Medical Sciences, Urmia, Iran , drrostamzadeh@yahoo.com
Abstract: (179 Views)
Background & Aims: Cytomegalovirus (CMV) is a member of herpesvirus family with high prevalence in the normal population, which can lead to life-threatening latent infection. This virus has potential oncogenicity and can be reactivated in terms of immune suppression. This study was conducted to investigate the prevalence of CMV in the patients with chronic lymphocytic leukemia (CLL).
Materials & Methods: To determine CMV prevalence, serum samples were collected from CLL patients after establishment of diagnosis by oncologist in Imam Khomeini Hospital, Urmia, Iran as well as from age-matched healthy subjects as control group. A total of 65 study participants, 33 males and 32 females, were included in this study in two groups, study group (n=31) and control group (n=34). All serum samples were tested for CMV-specific IgG and IgM antibodies using the enzyme-linked immunosorbent assay (ELISA) method. Data were analyzed by SPSS version 16.0. Student's t-test and Chi-square test were used for comparison of variables and between the categorical variables, respectively. The statistical significance considered as P < 0.05.
Results: The prevalence of CMV infection in all participants was 84.6%. The prevalence of CMV current infection (IgM positive) and previous infection (IgG positive only) were respectively 29.03% and 70.97% in the patient group and 97.05% and 2.95% in the control group.
Conclusion: Based on our results, previous exposure to CMV was significantly higher in the CLL patients compared with the control group. Good treatment and care strategies for the CLL patients can play an important role in preventing the reactivation of latent viral infections. Further studies and longtime monitoring should be done to know the factors affecting the reactivation of latent CMV infection and other latent viral infections in the CLL patients.
Materials & Methods: To determine CMV prevalence, serum samples were collected from CLL patients after establishment of diagnosis by oncologist in Imam Khomeini Hospital, Urmia, Iran as well as from age-matched healthy subjects as control group. A total of 65 study participants, 33 males and 32 females, were included in this study in two groups, study group (n=31) and control group (n=34). All serum samples were tested for CMV-specific IgG and IgM antibodies using the enzyme-linked immunosorbent assay (ELISA) method. Data were analyzed by SPSS version 16.0. Student's t-test and Chi-square test were used for comparison of variables and between the categorical variables, respectively. The statistical significance considered as P < 0.05.
Results: The prevalence of CMV infection in all participants was 84.6%. The prevalence of CMV current infection (IgM positive) and previous infection (IgG positive only) were respectively 29.03% and 70.97% in the patient group and 97.05% and 2.95% in the control group.
Conclusion: Based on our results, previous exposure to CMV was significantly higher in the CLL patients compared with the control group. Good treatment and care strategies for the CLL patients can play an important role in preventing the reactivation of latent viral infections. Further studies and longtime monitoring should be done to know the factors affecting the reactivation of latent CMV infection and other latent viral infections in the CLL patients.
Type of Study: orginal article |
Subject:
General
References
1. Geisler J, Touma J, Rahbar A, Söderberg-Nauclér C, Vetvik K. A Review of the Potential Role of Human Cytomegalovirus (HCMV) Infections in Breast Cancer Carcinogenesis and Abnormal Immunity. Cancers 2019;11(12):1842. Published 2019 Nov 22. doi:10.3390/cancers11121842 [DOI:10.3390/cancers11121842] [PMID] []
2. Wang YC, Wang NC, Lin JC, Perng CL, Yeh KM, Yang YS, Chiu CH, Chang FY. Risk factors and outcomes of cytomegalovirus viremia in cancer patients: a study from a medical center in northern Taiwan. J Microbiol Immunol Infect 2011;44(6):442-8. doi: 10.1016/j.jmii.2011.04.004 [DOI:10.1016/j.jmii.2011.04.004] [PMID]
3. Parry HM, Damery S, Hudson C, et al. Cytomegalovirus infection does not impact on survival or time to first treatment in patients with chronic lymphocytic leukemia. Am J Hematol 2016;91(8):776-81. doi:10.1002/ajh.24403 [DOI:10.1002/ajh.24403] [PMID] []
4. Vanura K, Rieder F, Kastner MT, et al. Chronic lymphocytic leukemia patients have a preserved cytomegalovirus-specific antibody response despite progressive hypogammaglobulinemia. PLoS One 2013;8(10):e78925. Published 2013 Oct 23. doi:10.1371/journal.pone.0078925 [DOI:10.1371/journal.pone.0078925] [PMID] []
5. Melchardt T, Weiss L, Greil R, Egle A. Viral infections and their management in patients with chronic lymphocytic leukemia. Leuk Lymphoma 2013;54(8):1602-13. doi: 10.3109/10428194.2012.755178 [DOI:10.3109/10428194.2012.755178] [PMID]
6. Bodey GP, Kontoyiannis D, Keating MJ. Infections in Patients With Chronic Lymphocytic Leukemia. Chron Lympho Leuk 2004:343-59. [DOI:10.1007/978-1-59259-412-2_19]
7. Zhang J, Chen X, Rong G, Xu T, Zhao H, Chen D, Wu L, Huang P, Wang F. Peripheral blood lymphocyte responses to cytomegalovirus seropositivity after allogeneic-hematopoietic stem cell transplantation. Onco Targets Ther 2018;11:5143-50. doi: 10.2147/OTT.S160178 [DOI:10.2147/OTT.S160178] [PMID] []
8. Reusser P. Management of viral infections in immunocompromised cancer patients. Swiss Med Wkly 2002;132(27-28):374-8. [Google Scholar]
9. Busca A. Viral infections in patients with hematological malignancies. Leuk Suppl 2012;1(Suppl 2):S24-S5. doi:10.1038/leusup.2012.15 [DOI:10.1038/leusup.2012.15] [PMID] []
10. Souza MA, Passos AM, Treitinger A, Spada C. Seroprevalence of cytomegalovirus antibodies in blood donors in southern, Brazil. Rev Soc Bras Med Trop 2010;43(4):359-61. doi: 10.1590/s0037-86822010000400004 [DOI:10.1590/S0037-86822010000400004] [PMID]
11. de Melo Silva J, Pinheiro-Silva R, Costa de Oliveira R, de Castro Alves CE, Barbosa AN, Pontes GS. Prevalence and recurrence rates of cytomegalovirus infection among patients with hematological diseases in the Western Brazilian Amazon: a cross-sectional study. Front Pub Health 2021:1504. [DOI:10.3389/fpubh.2021.692226] [PMID] []
12. Al-Kaabi Z. Seroprevelance of CMV Infection in Multi-Transfused Adult Patients with Haematological Malignancies: Single Iraqi Hematology Center Experience. Indian J Pub Health Res Dev 2019;10 (6):677. [DOI:10.5958/0976-5506.2019.01351.2]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Contact Information
Address: Urmia University of Medical Sciences, Jahad Ave., Urmia, I.R. Iran. Post code: 57147-83734. P.O. Box. 1138
Email: ijrabms
gmail.com
rabmsumsu.ac.ir
Tel / Fax: +984431937332/+984432240642
